- Home
- COSM
COSM
Cosmos Health Inc.
as 11-14-2024 4:00pm EST
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | THESSALONIKI |
| Market Cap: | 13.3M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 200.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $1.65 | Next Earning Date: | 11-26-2024 |
| Revenue: | $56,454,858 | Revenue Growth: | 15.73% |
| Revenue Growth (this year): | 7.57% | Revenue Growth (next year): | 22.58% |
Latest Cosmos Health Inc. News
COSM Breaking Stock News: Dive into COSM Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 days ago
Cosmos Health Issues Letter to Shareholders
ACCESSWIRE
14 days ago
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
ACCESSWIRE
2 months ago
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
ACCESSWIRE
2 months ago
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
ACCESSWIRE
2 months ago
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
ACCESSWIRE
2 months ago
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
ACCESSWIRE
2 months ago
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
ACCESSWIRE
2 months ago
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
Compare COSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COSM Cosmos Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.